Scot Ebbinghaus | Vice President and Therapeutic Area Head for Late-Stage Oncology Clinical Development

Scot Ebbinghaus, Vice President and Therapeutic Area Head for Late-Stage Oncology Clinical Development, Merck

Dr. Scot Ebbinghaus joined Merck Research Labs Late Stage Oncology Development in 2007. He is currently Vice President and Therapeutic Area Head for Late Stage Oncology Development with responsibilities for overseeing the Keytruda (pembrolizumab) development program and other late stage assets in the Merck Oncology portfolio and in Strategic Alliances.

Prior to joining Merck, Dr. Ebbinghaus was an Associate Professor at the University of Arizona in the Department of Medicine, Section of Hematology/Oncology.

Dr. Ebbinghaus earned his M.D. degree from the University of Missouri-Kansas City, completed his residency in Internal Medicine and his fellowship in Hematology-Oncology at the University of Alabama-Birmingham. Dr. Ebbinghaus has published over 60 manuscripts, and 5 book chapters in the field of Oncology. In addition to current responsibilities at Merck, Dr. Ebbinghaus is an attending physician at Fox Chase Cancer Center in Philadelphia in the Thoracic Oncology unit.


WVIC/WAC Day 2 - Nov 30 @ 10:00

Challenges & opportunities in moving immuno-oncology drugs into earlier lines of therapy

  • What are the challenges that need to be overcome before we can move immunotherapies into earlier stages?
  • What is effect of moving earlier in moving into adjuvant/neoadjuvant space? The need to understand progression much earlier in disease.
  • What are our current assumptions – what data do we need to pressure test them? How do we collect data? What data do we need?
last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall